Mount Sinai First in the East to Implant the WATCHMAN Device to Prevent Stroke in Atrial Fibrillation Patients
Mount Sinai experts were the first in the Eastern United States on March 23 to implant a newly FDA-approved device that prevents stroke in patients with arrhythmia.
The new device is designed to address atrial fibrillation, a malfunction that throws the heart out of rhythm, causing the upper chambers to beat too quickly. Often seen in aging patients, it interferes with electrical signals that drive the heartbeat. Patients with the condition have a five times greater risk of stroke, and a greater chance of having a more serious stroke.
The WATCHMAN device, the size of a quarter and shaped like a parachute, is implanted into the heart to close off the left-atrial appendage, a blind pouch of heart tissue where blood clots form and can then break off and travel in the blood stream to the brain and cause strokes. The device is inserted into the heart through a vein in the leg during a one-time, minimally invasive, catheter-based procedure in the Electrophysiology Laboratory.
"Blood-thinning medications like warfarin or Coumadin are quite effective in reducing the risk for stroke in patients with atrial fibrillation. However, many of our patients cannot, or will not, tolerate these medications because of the incidence of bleeding. The WATCHMAN device is a solution for such atrial fibrillation patients, since it similarly reduces their stroke risk, but averts their need for a lifetime of blood-thinners," says the electrophysiologist who led the procedure, Vivek Reddy, MD, Director of Arrhythmia Services at The Mount Sinai Hospital and the Mount Sinai Health System.
Dr. Reddy served as co-principal investigator for national clinical trials testing the WATCHMAN device. The recently published results of these trials revealed that the device offers an efficient alternative to warfarin, and prevents strokes just as well. Patients with the device implanted also had a 60 percent reduction in cardiovascular mortality and 34 percent reduction in all-cause mortality.
Warfarin is the most common treatment currently used to reduce stroke risk in patients with atrial fibrillation. However, warfarin is not well-tolerated by all patients and has significant risk for bleeding complications, and patients need to be closely monitored with bi-weekly blood tests.
"This advanced technology will be truly life-changing for many atrial fibrillation patients freeing them from not only the dangers of stroke risk, but also the daily challenges of long-term blood-thinning medication therapy," says Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital.
The newly U.S. FDA-approved WATCHMAN, made by Boston Scientific, Inc., is approved in more than 70 countries worldwide.
Dr. Reddy has served as a consultant to Boston Scientific, Inc., the manufacturer of the WATCHMAN device.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.